UQ's Dr Keith Chappell – one of the discoverers of the molecular clamp technology along with Prof Paul Young and Dr Daniel Watterson – will serve as lead scientific advisor to the new biotech.
The signatories of a new Biotech Social Pact with Europe and patients explain why healthcare calls for a new social contract, not a pharmaceutical strategy. As Europe continues its efforts to ...
Securities.io is not an investment adviser, and this does not constitute investment advice, financial advice, or trading advice. Securities.io does not recommend that any security should be bought, ...
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...
If you’re looking for biotech stocks to buy ... In the past three years, its total return was 0.95% in 2021, -13.69% in 2022 and 3.76% in 2023. Year-to-date (YTD), it’s up 2.91%, considerably ...